Ballentine Partners’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Ballentine Partners’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,000	Closed	-$336K	–	389
2018 Q3	$336K	Hold	20,000	–	–	0.02%	250
2018 Q2	$419K	Sell	20,000 -10,000	-33%	-$185K	0.02%	209
2018 Q1	$483K	Hold	30,000	–	–	0.03%	183
2017 Q4	$569K	Hold	30,000	–	–	0.03%	171
2017 Q3	$422K	Buy	30,000 +5,000	+20%	+$45.2K	0.02%	215
2017 Q2	$201K	Buy	+25,000	New	+$163K	0.01%	351

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ballentine Partners's SPPI Position: Q4 2018 in Review

Ballentine Partners sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q4 2018, closing a stake of 20,000 shares — an estimated $336K sold.

Ballentine Partners first reported a position in SPPI in Q2 2017 and held it in 6 quarters. The position peaked at $569K in Q4 2017. 176 funds tracked by Wall St. Rank hold SPPI as of Q4 2018.

Ballentine Partners reported no remaining Spectrum Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Ballentine Partners sold 20,000 Spectrum Pharmaceuticals Inc shares in Q4 2018, an estimated $336K.
Ballentine Partners first reported a position in Spectrum Pharmaceuticals Inc in Q2 2017 and held it in 6 quarters.
Ballentine Partners's Spectrum Pharmaceuticals Inc position peaked at $569K in Q4 2017.
176 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q4 2018.

Based on Ballentine Partners's 13F filing for Q4 2018, filed 4 Feb 2019.